Engagement in HIV care among Kenyan adults and adolescents: Results from a national population-based survey

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue SUPPL. 1, 2014, Pages

  Wafula, Rose ^a   Masyuko, Sarah ^a   Ng'ang'a, Lucy ^b   Kim, Andrea A ^b   Gichangi, Anthony ^b   Mukui, Irene ^a   Batuka, James ^c   Ngugi, Evelyn W ^b   Maina, William K ^a   Schwarcz, Sandra ^d  

^a MINISTRY OF HEALTH   (Kenya)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Cotrimoxazole; HIV; Kenya; Viral suppression

Indexed keywords

ADOLESCENT; ADULT; AGE FACTORS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; FEMALE; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; KENYA; MALE; MARITAL STATUS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; SEX FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; YOUNG ADULT;

EID: 84899049200     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000119     Document Type: Article

References (25)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS Report on the Global AIDS Epidemic. 2012. UNAIDS. Geneva, Switzerland: UNAIDS; 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report0-2012-en.pdf. Accessed July 7, 2013.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS. Geneva, Switzerland: UNAIDS; Available at: http://www.unaids.org/en/media/ unaids/contentassets/documents/document/2011/06/20110610-un-a-res-65-277-en.pdf. Accessed July 8, 2011.
5. Hamilton A, Garcia-Calleja JM, Vitoria M, et al. Changes in antiretroviral therapy guidelines: implications for public health policy and public purses. Sex Transm Infect. 2010;86:388-390.
6. Kimanga DO, Ogola S, Umuro M, et al. Prevalence and incidence of HIV infection, trends, and risk factors among persons aged 15-64 years in Kenya: results from a nationally representative study. J Acquir Immune Defic Syndr. 2014;66(suppl 1):S13-S26.
7. National AIDS Control Council (NACC). Kenya AIDS Epidemic Update 2011; 2012. Nairobi, Kenya: NAAC. Available at: http://www.unaids.org/en/dataanalysis/ knowyourresponse/countryprogressreports/2012countries/ce-KE-Narrative-Report. pdf. Accessed October 7, 2013.
8. Odhiambo J, Kellogg TA, Kim AA. Antiretroviral treatment scale-up among persons living with HIV in Kenya: results from a nationally representative survey. J Acquir Immune Defic Syndr. 2014;66(suppl 1): S116-S122.
9. National AIDS Control Council (NACC). Kenya National AIDS Strategic Plan 2009/10 - 2012/13: Delivering on Universal Access to Services. Nairobi, Kenya: NAAC; 2009. Available at: http://www.nacc.or.ke/nacc%20downloads/knasp-ii.pdf. Accessed October 8, 2013.
10. Waruiru W, Kim AA, Kimanga DO, et al. The Kenya AIDS indicator survey 2012: rationale, methods, description of participants, and response rates. J Acquir Immune Defic Syndr. 2014;66(suppl 1):S3-S12.
11. National AIDS and STI Control Program (NASCOP). Guidelines for Antiretroviral Therapy in Kenya 4th Edition. Nairobi, Kenya: NASCOP; 2011. Available at: http://nascop.or.ke/library/ART%20guidelines/ Guidelines%20for%20Antiretroviral%20Drug%20Therapy%20in%20Kenya.pdf. Accessed October 1, 2013.
12. National AIDS and STI Control Programme (NASCOP). 2007 Kenya AIDS Indicator Survey Final Report. Nairobi, Kenya: NASCOP; 2009. Available at: http://nascop.or.ke/library/3d/KAIS-2007-Final.pdf. Accessed September 15, 2013.
13. Maina WK, Kim AA, Rutherford G, et al. Kenya AIDS indicator surveys 2007 and 2012: implications for public health policies for HIV prevention and treatment. J Acquir Immune Defic Syndr. 2014;66(suppl 1): S130-S137.
14. Muthulingam D, Chin JCS, Hsu L, et al. Disparities in engagement in care and viral suppression among persons with HIV. J Acquir Immune Defic Syndr. 2013;63:112-119.
15. Cohen SM, Van Handel MM, Branson BM, et al. Vital Signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep. 2011;60:1618-1623.
16. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8: e1001056. doi: 10.1371/journal.pmed.1001056.
17. Ingle S, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24:2717-2725.
18. Geng EH, Bwaba MB, Muyindike W, et al. Failure to initiate ART, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr. 2013;63:e64-71.
19. World Health Organization (WHO). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, 2013. Geneva, Switzerland: WHO; 2013. Available at: http://apps.who.int/iris/bitstream/10665/ 85321/1/9789241505727-eng.pdf. Accessed October 15, 2013.
20. Jain V, Liegler T, Kabami J, et al. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013;56:598-605.
21. Kranzer K, Lawn SD, Johnson LF, et al. Community viral load and CD4 count distribution among people living with HIV in a South Africa township: implications for treatment as prevention. J Acquir Immune Defic Syndr. 2013;63:498-505.
22. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-110.
23. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US department of defense HIV natural history study. J Infect Dis. 2009;200: 1714-1723.
24. Madec Y, Boufassa F, Rouzioux C, et al; for the SEROCO Study Group. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis. 2005;40: 1350-1354.
25. Das M, Raymond HR, Chu P, et al. Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from national HIV behavioral surveillance, 2004-2011 [letter]. J Acquir Immune Defic Syndr. 2013;63:e84-6. doi: 10.1097/QAI.0b013e31828ed2e4.